health systems and covid 19
play

Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family - PowerPoint PPT Presentation

Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family Center for Health Systems Science & Innovation April 13, 2020 Agenda Overview of Health System Approaches via the Keck Medicine of USC Lens 2 Norbert Gehr and David


  1. Health Systems and COVID-19 Michael Hochman, MD, MPH Gehr Family Center for Health Systems Science & Innovation April 13, 2020

  2. Agenda • Overview of Health System Approaches via the Keck Medicine of USC Lens 2

  3. Norbert Gehr and David Goldstein 3

  4. Protecting Healthcare Workers • How does SARS-CoV-2 spread? 4

  5. Protecting Healthcare Workers • Deep cleaning • Patient and healthcare worker wear masks 5

  6. N95s • For aerosolizing procedures 6

  7. High Risk Employees • 65+ • Chronic conditions • Pregnancy 7

  8. Triage System 8

  9. Telemedicine 9

  10. Telemedicine 10

  11. Telemedicine 11

  12. Telemedicine 12

  13. Testing 13

  14. Testing • Therapeutic Purposes: - Critically ill patients • Public Health Purposes: - Self-isolation - Contact tracing 14

  15. Evidence-Based Treatment 15

  16. ICU Care 16

  17. Principles “While there is pressure to fast-track the evaluation of COVID-19 treatment, adherence to rigorous scientific methods to evaluate potential COVID-19 therapies remains just as critical as ever to avoid unintended consequences. Taking “short-cuts” in the evaluation of new therapies may lead to widespread use of ineffective treatments with associated safety concerns.” 17

  18. Principles “Some political advocacy groups are promoting “right to try” policies to enable patients to access unapproved and “off-label” therapies for COVID- 19 before rigorous evaluation. Prior experience has shown that that practices can cause more harm than good. Our team favors reserving experimental therapies for research settings. “Right to try” policies risks exposing patients to safety concerns without offering them benefits.” 18

  19. Hydroxychloroquine “The FDA has authorized an emergency use approval for hydroxychloroquine, however debate remains about whether the benefits outweigh the risks. In one small randomized trial, hydroxychloroquine failed to hasten clinical recovery vs. control patients, however in another hydroxychloroquine led to modestly faster clinical recovery, and lower rates of radiological pneumonia. Neither trial has been peer reviewed.“ 19

  20. Advanced Care Planning 20

  21. Easing of Social Distancing “As COVID-19 infection and morbidity rates peak in the U.S., experts have begun suggesting validated approaches -- such as “suppress and lift” policies, “targeted approaches” and immunity testing -- as well as criteria for cautiously easing social and economic restrictions without triggering sudden and dramatic recurrences of disease spread that could overwhelm the healthcare system.“ 21

  22. Contact Tracing 22

  23. Digital Contact Tracing 23

  24. Keck Evidence-Based COVID Resource Keck.usc.edu/coronavirus/ 24

  25. Gehr-Akido-AltaMed COVID Self- Assessment Tool Covidassessment.org 25

  26. Gehr-Akido-AltaMed COVID Self- Assessment Tool 26

  27. Gehr-Akido-AltaMed COVID Self- Assessment Tool 27

  28. Thank you • Questions? Speaker Contact: mhochman@usc.edu 28

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend